Description of Collaborative Activity: |
The Working Group focuses on potential MERS-CoV countermeasures, to include therapeutics (i.e., antivirals, monoclonal antibodies, and others) and vaccines. The working group was asked to assess the following:
a) inventory of potential therapeutics (and vaccines) under development/investigation and by what groups
b) how far along are they in pre-clinical development (in-vitro, animal studies/mice/non- human primates) and what data are available
c) timelines for animal studies and scale-up including when human trials (phase 1, phase 2, open-label studies) can be started
d) safety and regulatory issues for IND, EUA, and clinical studies
e) prioritization for clinical trials based upon pre-clinical data and scientific assessment of available data |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
